Products
Sorafenib is commercially available in the form of film-coated tablets (Nexavar). It has been approved in many countries since 2006.
Structure and properties
Sorafenib (C21H16ClF3N4O3, Mr = 464.8 g/mol) is present in drugs as sorafenibtosilate, a white to yellowish or brownish powder that is practically insoluble in water.
Effects
Sorafenib (ATC L01XE05) has antiproliferative, antitumor, and antiangiogenic properties. The effects are due to inhibition of several kinases (multi-kinase inhibitor). These include RAF, c-KIT, FLT, VEGFR and PDGFR. The half-life is between 25 to 48 hours. In clinical trials, sorafenib has been shown to statistically significantly prolong survival.
Indications
- Hepatocellular carcinoma
- Advanced renal cell carcinoma
- Thyroid carcinoma (end stage)
Dosage
According to the professional information. Tablets are taken twice daily fasting or with a light, low-fat meal.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
Sorafenib is metabolized by CYP3A4, UGT1A9, and UGT1A1 and undergoes marked enterohepatic cycling.
Adverse effects
The most common potential adverse effects include: